Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)
February 27, 2024 07:10 AM Eastern Standard Time STRASBOURG, France & MONTREAL & BOSTON–(BUSINESS WIRE)–Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO). Stephan will oversee the development of Domain’s proprietary … Continue reading Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)